Setup

Repay Holdings (RPAY) is a specialty payment processor ($300M market cap, $3.13/share) trading at 3.4x forward P/E — roughly 80% below payment sector comps. On April 13, the Board adopted a poison pill with a 12.5% ownership trigger. What makes this interesting isn't the pill. It's who's on the other side, what they just finished doing, and the $372M acquisition the Board is trying to protect.

What the filing says

The 8-K (April 14, Items 1.01/3.03/5.03/7.01) discloses a stockholder rights plan adopted "in response to the significant accumulation of the Company's common stock." One-year duration, expires April 13, 2027. Shareholder-friendly design: a qualifying offer provision allows holders of 20%+ to force a special meeting vote after 90 business days; no dead-hand features; Board commits to seek stockholder approval for any extension.

The accumulator is Forager Fund, L.P. — 11.9% ownership (10.2 million shares, $34.7M cost basis) per their 13D/A filed April 3. The 13D language explicitly lists "extraordinary corporate transaction (including, but not limited to a merger, take-private, reorganization or liquidation)" among the actions Forager may pursue. They upgraded from 13G to 13D on March 12.

But the pill isn't the whole story. On March 30, RPAY announced a $372M all-cash acquisition of KUBRA Data Transfer, funded by a new $500M term loan. The stock dropped 17%. On April 9, a second activist — Veradace Partners, 8.4% holder — issued a public letter demanding KUBRA termination and two board seats. The Board reaffirmed KUBRA on April 13, the same day it adopted the pill.

Combined activist ownership: 20.3%. The qualifying offer provision threshold: 20%. The pill may be as much about protecting the KUBRA deal as about blocking a hostile takeover.

What the market thinks

At $3.13, the stock is up 30% in one week but sits at 22% of its 52-week range ($2.30-$6.05). Analyst consensus: 5 Buy / 2 Hold, mean target $6.57 (+109% upside).

Before Forager showed up, RPAY had negative trailing alpha (-18.3% annualized in a regression against SPY and IPAY). The 3.4x P/E is not a mispricing — it's the market's standalone valuation for a declining payment processor. The $0.73 premium over the pre-catalyst price (≈$2.40) is activist optionality. Working backwards from a simplified binary (takeout at $6 vs. no-takeout at $2.40), the market implies roughly 20% probability of a successful takeout.

86% of trailing return variance is idiosyncratic. This is a pure stock-specific catalyst — not a sector or market bet. No liquid options chain, so market-implied probabilities can't be read directly.

Why the gap exists

The market sees a generic situation: activist buys cheap stock, board defends with pill.

Forager Capital Management completed a take-private of Quipt Home Medical 28 days ago. The sequence: 13D filed December 2024, hostile bid at $3.10/share, board rejected, eventual take-private with Kingswood Capital at $3.65/share (162% premium to unaffected price), 98.9% shareholder approval, completed March 16, 2026.

The RPAY timeline is tracking the same sequence: quiet accumulation, 13G-to-13D upgrade (March 12), continued buying past 10%, board defensive action (April 13). This is step 4 of a playbook that ran to completion one month ago.

Separately, Forager + Veradace at combined 20.3% already meet the 20% threshold to invoke the pill's qualifying offer provision — forcing a special meeting vote if the Board doesn't act within 90 business days. The Board wrote this provision into the pill themselves.

Risks (ranked by impact)

1. KUBRA closes. The Board has signed a $372M acquisition with committed financing and no shareholder vote required. If KUBRA closes, RPAY takes on 4x debt/EBITDA. The activist campaign likely settles for board seats and governance concessions, and the stock drifts to $3.50-$4.00 over 12-18 months as the combined entity de-levers. The Board wants this deal.

2. Convertible debt raises the bar. $287.5M of 2.875% convertible notes due July 2029 at $13.02 conversion (deeply out-of-the-money). In a change-of-control, noteholders can demand repurchase at par — ≈$291M cash. Total takeout cost: ≈$300M equity + ≈$291M debt = $591M+. At a $6 takeout: ≈$855M. This limits the buyer pool to parties who can write a $600M+ check.

3. No standalone alpha. The entire bull case is activist-created optionality. If Forager exits or goes passive, the stock reverts to $2.00-$2.50. There is no fundamental floor beyond what the market already prices.

4. Break fee unknown. The KUBRA merger agreement's termination fee isn't in the 8-K. Typical break fees for a $372M deal are $11-19M (3-5%). A high fee makes activist-driven termination more expensive.

Catalysts (with dates)

• May 11, 2026: Q1 earnings (est. $0.21 EPS). Tests whether Q4 miss (-9.4%) was one-time or trend.
• Q2 2026: KUBRA expected close. This is the fork — if it terminates, the takeout path clears. If it closes, the thesis narrows to a de-leveraging play.
• Forager-Veradace group 13D (watch for in next 30-60 days): If they file a group Schedule 13D, it confirms coordination and strengthens the qualifying offer mechanism. Absence would be mildly bearish.
• ~October 2026: 90 business days from any qualifying offer — the window for Forager + Veradace to force a special meeting vote.
• April 13, 2027: Pill expiration. The hard deadline.
• TBI (TrueBlue) — leading indicator: Similar poison pill expiring May 13, 2026 (29 days). HireQuest has made hostile bids ($12.30, $7.50, both rejected). How TBI resolves will inform RPAY probability estimates.

What would change our mind

• KUBRA closes + Forager signs cooperation agreement. The activist premium evaporates. This is the most likely kill condition. Observable in real time, Q2 2026.
• Forager sells shares. Any Form 4 showing disposition ends the thesis immediately.
• KUBRA break fee exceeds $20M. At 5%+ of deal value, termination becomes prohibitively expensive for activists.
• Q1 earnings miss > 15%. Would push standalone value below $2.00 and weaken the takeout case.

Evidence